Verapamil and beta cell function in adults with recent-onset type 1 diabetes.
Verapamil and beta cell function in adults with recent-onset type 1 diabetes.
复制标题
DOI:
10.1038/s41591-018-0089-4
复制
发表时间:
2018-08
期刊:
影响因子:
82.9
通讯作者:
Shalev A
中科院分区:
文献类型:
--
作者:
Ovalle F;Grimes T;Xu G;Patel AJ;Grayson TB;Thielen LA;Li P;Shalev A
Pancreatic beta cell loss is a key factor in the pathogenesis of type 1 diabetes (T1D), but therapies to halt this process are lacking. We previously reported that the approved antihypertensive calcium-channel blocker verapamil, by decreasing the expression of thioredoxin-interacting protein, promotes the survival of insulin-producing beta cells and reverses diabetes in mouse models. To translate these findings into humans, we conducted a randomized double-blind placebo-controlled phase 2 clinical trial (NCT02372253) to assess the efficacy and safety of oral verapamil added for 12 months to a standard insulin regimen in adult subjects with recent-onset T1D. Verapamil treatment, compared with placebo was well tolerated and associated with an improved mixed-meal-stimulated C-peptide area under the curve, a measure of endogenous beta cell function, at 3 and 12 months (prespecified primary endpoint), as well as with a lower increase in insulin requirements, fewer hypoglycemic events and on-target glycemic control (secondary endpoints). Thus, addition of once-daily oral verapamil may be a safe and effective novel approach to promote endogenous beta cell function and reduce insulin requirements and hypoglycemic episodes in adult individuals with recent-onset T1D.
登录
查看更多内容
DOI:
10.1016/j.bbrc.2005.08.161
发表时间:
2005-10-28
影响因子:
3.1
作者:
Minn, AH;Pise-Masison, CA;Shalev, A
通讯作者:
Shalev, A
影响因子:
7.7
作者:
AFZAL, N;GANGULY, PK;DHALLA, NS
通讯作者:
DHALLA, NS
影响因子:
8.2
作者:
Liu, E. H.;Digon, B. J., III;Harlan, D. M.
通讯作者:
Harlan, D. M.
影响因子:
3.7
作者:
Lachin, John M.;McGee, Paula L.;Skyler, Jay
通讯作者:
Skyler, Jay
影响因子:
16.2
作者:
Davis, Asa K.;DuBose, Stephanie N.;Greenbaum, Carla J.
通讯作者:
Greenbaum, Carla J.